Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tumor adverse events. And now with a $150m series A venture capital round announced on 20 March, the company plans to develop its first therapeutic candidates from preclinical all the way through initial clinical trial data.
Key Takeaways
-
Clasp Therapeutics launched with a $150m series A round to develop off-the-shelf T-cell engagers based on research conducted at Johns Hopkins University.
-
The bispecific antibody-like therapeutics target intracellular mutated oncogenes found on the surface of tumor cells in the presence of specific HLA subtypes
Cambridge, MA- and Rockville, MD-based Clasp emerged from the labs of cancer genetics specialist Bert Vogelstein and immuno-oncology researcher Drew Pardoll at Johns Hopkins University, and Catalio Capital Management and Third Rock Ventures incubated the start-up for a few years before Clasp’s official launch. CEO Rob Ross came to the company from Surface Oncology, Inc., where he was CEO until its sale to Coherus BioSciences, Inc. in an all-stock deal valued at $65m in mid-2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
